H1N1 2009 Pandemic Analysis: Evaluation and Scenarios for Post-Pandemic Planning

The 2009 pH1N1 pandemic took the lives of 428 individuals and led to 8,678 hospitalizations in Canada. Despite these sobering numbers, it appears that as a result of existing pandemic preparation measures, Canadian health services were able to mitigate the effects of the virus and avoid a more serious public health crisis. However, it must be emphasized that pH1N1 proved to be generally mild and that, despite this, many issues emerged during the pandemic, raising questions about the capacity of the healthcare system and the appropriate level of intervention in such circumstances. Since pH1N1, the notion of a pandemic is no longer as abstract as it once appeared, either for public health officials or for the general population. Using pH1N1 Canadian data as a baseline, this analysis seeks to inform post‐pandemic public health discussions that focus on the evaluation of antiviral and vaccine interventions, considering several plausible hypothetical scenarios. Using empirically supported pandemic and economic mathematical models,the objectives of the research were to evaluate:

• The life and economic impact of pH1N1 in Canada;
• The effect of reported antiviral and vaccine interventions in mitigating the effects of the pandemic;
• The possible life and economic impacts of a similar influenza pandemic under several hypothetical cases.

In particular:
• If it occurred in the fall instead of in the spring,
• If its effects were moderate or severe, rather than mild,
• If antiviral agents were not used or if their use were widespread

Methods and Approach:
The approach employed an age‐dependent Susceptible‐Exposed‐Infected‐Recovered pandemic model, coupled
with a macroeconomic model to estimate life and economic impacts. The life impacts evaluated included the attack rate, hospitalizations, and deaths; the economic analysis examined the effect of the pandemic on absenteeism and direct health costs. Healthcare resource use included only those costs directly related to the treatment of pH1N1 cases and took into account GP visits, emergency department visits, and hospitalizations. Absenteeism was assumed to be proportional to the number of infectious individuals and any hospitalizations that occurred among the employed. Given the interest in understanding the full potential impact of pH1N1 in Canada, the analysis evaluated the following scenarios:

• Pandemic pH1N1, with and without each combination of reported antiviral and vaccine intervention used;
• Spring‐start moderate and severe pandemics, with and without vaccination and antiviral interventions (where antiviral use could be either at 2009 levels or more widespread); and
• Fall‐start moderate and severe pandemics, with and without vaccination and antiviral interventions (where antiviral use could be either at 2009 levels or more widespread)”

Disentangling the relative contributions of antivirals and vaccines has been a challenge given their joint use in a highly dynamic process such as a pandemic. In terms of hospitalizations, antivirals would have independently accounted for 7.6% of the cases saved and vaccines for 85.4%. The balance of 7.0% is reflective of the synergistic use of both antivirals and vaccines together. In terms of deaths, antivirals would have independently accounted for 55.1% of the cases saved and vaccines for 65.0%. The excess of 20.1% reflects the common ability of both interventions to prevent death. On its own, antiviral use was considered very cost‐effective at an estimated $2,002 cost for each QALY gained. Once healthcare costs saved were taken into account, rather than a net cost per QALY, antivirals resulted in a net savings of $1,077 for each QALY gained. That is, antiviral use paid for itself in terms of healthcare costs saved. During the period of pH1N1, a reported 50.4million doses of vaccine were purchased, of which approximately 14.6 million were estimated to have been used. On its own, vaccine use was estimated to have an incremental cost‐effectiveness ratio (ICER) of $2,076 cost per QALY gained when the cost of vaccine not used was excluded. With respect to the total amount of vaccine which had been purchased, an ICER of $17,317 cost per QALY gained had been estimated. Both measures indicate that vaccines can also be considered very cost effective.

The present research is focused on making broad conclusions about the effectiveness of antiviral and vaccine use by providing general scenario analysis to inform policy discussions in the aftermath of the pH1N1 pandemic. The research is oriented towards population health management and future risk mitigation issues, as they relate to Canadian life and economic effects of pH1N1. The work demonstrates how such effects could have changed under different severity and timing scenarios. The analysis suggests that the joint use of antiviral and vaccine intervention played a pivotal role in blunting the potential negative impacts of pH1N1. Without the reported use of antivirals and vaccine during 2009, pH1N1 impacts could have been at least twice as large. The analysis revealed that antivirals played a therapeutic role for the sick, whereas vaccination served as the primary means by which infection could be prevented. These interventions appear to have been very cost effective, both independently and as part of a joint intervention effort.



You may also be interested in

Find out how CANCEA can help you on your path to better decisions and prosperity.

Trusted By

Organizations that have trusted CANCEA to provide key insights and analysis include: